Evidence map›Paper›PMID 42507643›Full record

ArticlePloS one2026

Enhancing missense variant classification in predicted intrinsically disordered regions.

Rohan D Gnanaolivu, Steven N Hart

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rohan D GnanaolivuDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID https://orcid.org/0000-0001-6995-6340
Steven N HartDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID https://orcid.org/0000-0001-7714-2734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classifying disease-causing missense variants in intrinsically disordered regions (IDRs) remains a significant challenge, with over 25% of known deleterious variants occurring in these regions. Existing in silico missense variant predictors that predict variant classification generally perform better in ordered regions of the protein, limiting their effectiveness. To address this, we developed a machine learning methodology that integrates global IDR conformation (gIDRc) features from ALBATROSS, phase separation (PS) features from BioPython, and 1024-dimensional protein embeddings from ProtTransBertBFD generated for both wild-type (WT) and mutant IDR sequences. IDR boundaries were defined using the AlphaFold-RSA predictions, which identifies disordered regions based on AlphaFold2 pLDDT scores and relative solvent accessibility. Using ClinVar variant classifications as ground truth, AlphaMissense, EVE, and ESM1b were the highest scoring unsupervised in silico missense predictors for IDR variants. Our baseline model, using only IDR-specific features achieved competitive performance on the hold-out test set with a PR-AUC of 0.817. Critically, when these IDR features were combined with these methods we saw significant overall improvement. The AlphaMissense-Enhanced model increased its PR-AUC from 0.807 to 0.919. Similarly, ESM1b-Enhanced improved PR-AUC from 0.679 to 0.845 and EVE increased from 0.591 to 0.910. These results demonstrate the effectiveness of our enhancements for classifying missense variants in IDRs and highlight its ability to complement existing in silico missense predictors.

Indexed as

Intrinsically Disordered ProteinsMutation, MissenseComputational BiologyHumansMachine LearningProtein ConformationIntrinsically Disordered Proteins

Identifiers

PMID42507643
PMCPMC13405113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.